Therapeutics Solutions International Signs Agreement with Beijing Regenesis Biotechnology
November 11 2019 - 9:00AM
InvestorsHub NewsWire
Therapeutics Solutions International Signs Agreement with
Beijing Regenesis Biotechnology to License and Develop Patent for
Anti-Aging use of Cord Blood Plasma and
NanoStilbene
Company Expands Use of
Commercially Available Anti-Inflammatory Nanoparticle Nutraceutical
NanoStilbeneā¢ into Anti-Aging Market
OCEANSIDE, CA --
November 11, 2019 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today the
signing of a Letter of Intent with Beijing Regenesis Biotechnology
Co. Ltd., of Beijing China to develop and commercialize the
anti-aging properties of cord blood plasma combined with
NanoStilbene.
"Our Company is the
leading entity in implementation of anti-aging regenerative
medicine in China. We have previously commercialized novel
technologies for rejuvenation of testicular and ovarian function"
said Dr. Fei Li, Chief Executive Officer of Beijing Regenesis.
"Cord blood components have been used for more than a Century in
medicine with an excellent safety profile. We are excited to
utilize the new technology developed by TSOI in order to reduce and
potentially even reverse the biological aspects of
aging."
"Having previously
collaborated with Beijing Regenesis, I am excited to expand our
work in the area of anti-aging medicine. There are
publications from Stanford University [1]
and Harvard
University [2]
that have
shown that if the circulation of an aged mouse is connected to the
circulation of a young mouse, various factors secreted by young
mice induce an anti-aging/rejuvenating effect on organs/tissues of
aged mice. Following this logic, other studies have
demonstrated that human cord blood plasma, when administered to
aged mice results in restoration of brain function and improved
cellular function in the hippocampus [3]"
said
Dr.
Feng Lin,
Chief Scientific Officer of TSOI. "We are very excited to
commercialize the use of cord blood plasma with NanoStilbene
as a
means of translating the animal parabiosis experiments into
humans."
"Our Company is about
fast forwarding the
development of novel
medical technologies. Based on the reputation, success,
and ingenuity of Beijing
Regenesis, we believe we have found an ideal commercialization
partner" said Timothy Dixon,
President and Chairman of TSOI. "We are especially grateful for
Congressional Candidate Famela Ramos, our Director of Business
Development, for having arranged our meeting and providing an
excellent venue for signing of the Letter of Intent."
[1]
Conboy
et al. Rejuvenation
of aged progenitor cells by exposure to a young systemic
environment. Nature.
2005 Feb 17;433(7027):760-4. https://www.ncbi.nlm.nih.gov/pubmed/15716955
[2]
Katsimpardi
et
al. Vascular
and neurogenic rejuvenation of the aging mouse brain by young
systemic factors. Science.
2014 May
9;344(6184):630-4. https://www.ncbi.nlm.nih.gov/pubmed/24797482
[3]
Castellano et
al. Human
umbilical cord plasma proteins
revitalize hippocampal function in
aged mice.
Nature 2017
Apr 27;544(7651):488 492.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586222/
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and e-commerce at www.youcanordernow.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024